tci 2013 biobasque and the basque biocluster
DESCRIPTION
By Cristina Oyón, SPRI - Basque Government, presented at the 16th TCI Global Conference, Kolding 2013.TRANSCRIPT
BioBasque and the Basque BioClusterCristina Oyón
Breakout Session: Clusters and smart specialisation strategies: design and implementation
5 September 2013
From the different theoretical ways of smart diversification, could the radical foundation of a science based new industrial activity be a sound lever for productive transformation?
Source: The Basque Country Competitiveness Report, 2013 - Orkestra
The Question
The Strategy
• First strategy specifically designed (2001-2002) to promote lifesciences in Spain
• Aim: to develop a new business sector in the Basque Country reated to biosciences
• Integrated approach built around three axis: knowledgegeneration, business development, dynamisation
• Mission: to establish a biocluster capable of competinginternationall
• Cuantitative objectives: 40 new companies, 3.000 new jobs
• Chosen as RegioStars 2011 Awards (EU) finalist, among 66 initiatives from 18 countries, awards to most innovativeregional projects which have received funding from the EU regional/ cohesion policy
The Health Subsystem
DEMOTEK: medical devices effectiveness demonstration unit
The Government Support
Source: The Basque Country Competitiveness Report, 2013 - Orkestra
The Budget
Rough figures of public investment in 2012
Knowledge generation
~20 M€
Sector dynamisation
~0,5 M€
Business development
~5 M€
18
Service Provision
Diagnostics
Therapeutics
Other
Antigens, antibodies one-stop shop
Early drug discovery in-vivo
Food, environmental safetyDrug development services
Drug screening & analysis
Clean labs, bio-safety
Engineers and consultants agri-food
Bromatology lab
Drug production support
Ophthalmological sanitary products
Polymeric dispersion µ-beads
Bio-software systems
Natural chem. fungicides (crops)Cell-based assays (drug discovery)
Metabolomic Dx
Vaccines, allergology
Drug development (CNS)
Regenerative medicine
Full-cycle Pharma
Tissue engineering, cell therapy
Biotech cosmetics
Nanomedicines (biocompatible nanoparticles)Drug development, distribution
Non-invasive Dx (ophthalmology )
Genetic Dx methods
Genomic IVD tests
In-vitro Dx tests Dx & Tp animal health
The Outcome
The Outcome
BioBasque is recognized as a BioRegion at national and international scale. We are the 4th community in Spain regarding nr of biotechs, accounting for the 9%, well above the 6% of Spanish GDP that supposes the Basque economy.
In 2007-2011 the nr of biotechs has been multiplied by 1,4. The sector employs directly 1.600 persons in R&D, representing 5,8% of total employment in R&D. The R&D personnel accounts for the 50% of total employment
The sector invoices more than 300 M€. 57% of biotechs have increased its invoicing in the period 2007-2011. 31% have maintained it.
60% of biotechs are less than 10 years old. 90% of them are internationalized
The Future
TRANSVERSAL CAPACITIES
• Biosciences
• Nanosciences
• Advanced manufacturing
MARKETS
• Movility & Transport
• Digital World
• Science Industry
• Ageing / Health
• Energy
Bio-NanoSciences
SmartManufacturing
Energy
EXISTING PRIORIZITATION
(PCTI 2015)
REFLECTION PROCESS
METAPRIORITIES
REFLECTION PROCESS
PILOTPROJECTS
Source: The Basque Country Competitiveness Report, 2013 - Orkestra
Cristina Oyón
Head of Strategic Initiatives, SPRI
www.biobasque.org